Gene test mix-up brings scrutiny to industry
By Alejandro Martínez-Cabrera,
San Francisco Chronicle
| 06. 11. 2010
[Quotes CGS's Jesse Reynolds]
Last week, retired marketing specialist Nora Probasco called her brother with a half-serious, half-joking question: Was she adopted?
The issue came up after the 59-year-old genealogy hobbyist from Louisville, Ky., received the results of a test she took through 23andMe, a Google-backed firm that allows people to learn more about their ancestry and some medical conditions through DNA analysis.
"I was shocked," she said. "What it came down to, the way I know to read them, is that my mom is not my mom."
To her relief, it turned out to be a mistake. Last Friday, the Mountain View firm acknowledged in a post on its Web site that it mixed up the samples of 96 clients and sent them the wrong ones. The company corrected the mistake relatively quickly, but observers see the potential for similar errors that could lead individuals to make ill-informed decisions regarding their health.
The company, which was founded in 2006, said in an e-mail that the mistake occurred when a tray with 96 samples was misplaced. The company added that new procedures have been...
Related Articles
By Emily Mullin, Wired | 11.14.2023
In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.
The gene-editing treatment aims to permanently lower cholesterol...
By Carissa Wong, Nature | 11.16.2023
In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since...
By Emily Mullin, Wired | 11.16.2023
The first medical treatment that uses Crispr gene editing was authorized Thursday by the United Kingdom.
The one-time therapy, which will be sold under the brand name Casgevy, is for patients with sickle cell disease and a related blood disorder...
By Alexis Heng, UCA News | 11.13.2023
In recent years, Singapore has increasingly leveraged new reproductive technologies to overcome the country's rapidly aging demographics and dismal fertility rate, which hit a new low in 2022.
Hence, it would be timely for Singapore’s Bioethics Advisory Committee (BAC) to...